MetVax
Latest Information Update: 11 Jan 2026
At a glance
- Originator D5 Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 Sep 2025 D5 Pharma has patent protection for MetVax in USA (D5 Pharma pipeline, September 2025)
- 15 Sep 2025 Preclinical trials in Cancer in USA (Parenteral) prior to September 2025 (D5 Pharma pipeline, September 2025)